JNJ-4916 / J&J - LARVOL DELTA

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=126 | Recruiting | Sponsor: Johnson & Johnson Enterprise Innovation Inc. | Trial completion date: Aug 2032 ➔ Feb 2033

Monotherapy • Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=126 | Recruiting | Sponsor: Johnson & Johnson Enterprise Innovation Inc. | N=96 ➔ 126

Enrollment change • Monotherapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phase I study of intratumoral administration of JNJ-87704916, an oncolytic virus, as monotherapy and in combination with cetrelimab in advanced solid tumors (ESMO 2025) - "Two pts with IO refractory advanced melanoma experienced Partial Responses at 6 weeks that are still ongoing at 20 and 25 weeks, including evidence of response in uninjected lesions and deepening of response with time. Conclusions IT injection of JNJ-4916 demonstrated acceptable safety when combined with CET, with evidence of systemic disease control in 2 pts with anti-PD1 refractory metastatic melanoma."

Combination therapy • IO biomarker • Metastases • Monotherapy • Oncolytic virus • P1 data • Melanoma • Oncology • Solid Tumor • CD40 • IFNG • IL12A

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: Johnson & Johnson Enterprise Innovation Inc. | Trial completion date: Nov 2033 ➔ Aug 2032

Monotherapy • Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: Johnson & Johnson Enterprise Innovation Inc. | N=66 ➔ 96

Enrollment change • Metastases • Monotherapy • Oncolytic virus • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: Johnson & Johnson Enterprise Innovation Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Monotherapy • Oncolytic virus • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=66 | Not yet recruiting | Sponsor: Johnson & Johnson Enterprise Innovation Inc.

Metastases • Monotherapy • New P1 trial • Oncolytic virus • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor